Devices, kits, and assays are provided for the testing and monitoring of hemoglobin, anemia, glucose-6-phoshate dehydrogenase, and glucose-6-phosphate dehydrogenase deficiency in an individual.

Provided is a method for identifying and treating a pregnancy devoid of uterine fetal or embryonic tissue in a subject by determining a concentration of alpha-fetoprotein (AFP) in a specimen evacuated from the uterus of the subject; comparing the concentration of AFP to a reference value; wherein when the AFP concentration in the specimen evacuated from the uterus is below that of a reference value, absence of uterine fetal or embryonic tissue is indicated. Also provided is a method for identifying and treating a presence of fetal or embryonic tissue in a location of a subject other than the uterus by determining a concentration of AFP in a non-uterine specimen obtained from the subject; comparing the concentration of AFP in the specimen to a reference value; wherein when the AFP concentration in the specimen is above that of a reference value, presence of fetal or embryonic tissue is indicated.

Provided herein is a method for determining the volume or hemoglobin content of an individual red blood cell in a sample containing a population of red blood cells. The method may be performed on a hematology analyzer. Also provided are a hematology analyzer for performing the method and a computer-readable medium containing programming for performing the method.

Devices, systems, and methods for measuring the blood loss of a subject during a medical procedure. Blood and other fluids are received within a container, and a blood measurement device determines the hemoglobin concentration of the fluid within the container. The blood measurement device can also calculate the estimated blood loss of the subject based upon the determined hemoglobin concentration and the volume of the fluid within the container and the patient's hemoglobin.

A method of processing a fecal sample from a human subject comprising removing a portion of a collected fecal sample and adding the removed portion of the sample to a buffer that prevents denaturation or degradation of blood proteins found in the sample, and detecting the presence of human blood in the removed portion of the fecal sample. The method further comprises stabilizing the remaining portion of the fecal sample.

A sensor according to a first embodiment of the present invention includes a flow channel to permit passage of a specimen, a first detection part that is located in the flow channel and has a first ligand specifically bindable to a first material in the specimen, and a second detection part that is located downstream of the first detection part in the flow channel and has a second ligand specifically bindable to the first material and/or a second material in the specimen.

Disclosed is an in vitro method for assessing or predicting the response of a human patient to treatment of periodontal disease. The method is based on the insight to determine biomarker proteins. Accordingly, in a sample of saliva of a patient, the concentrations are measured of certain protein combinations. One such combination is Hemoglobin subunit delta (Hb-delta) and Pyruvate kinase (PK). Another such combination is Keratin-4 (K-4) and at least two of Alpha-1-acid glycoprotein (A1AGP), Pyruvate Kinase (PK) and Matrix metalloproteinase-8 (MMP-8). A third combination is Alpha-1-acid glycoprotein (A1AGP), Pyruvate Kinase (PK) and S100 calcium binding protein A8 (S100A8). Based on the concentrations as measured, at least one value is determined reflecting the joint concentrations for said proteins. This at least one value may indicate the probability that human patient has been or will be successfully treated for the periodontitis. The at least one value can be compared with at least one threshold value reflecting in the same manner the joint concentrations associated with successful treatment of periodontitis. The comparison allows assessing whether the testing value is indicative of the periodontal treatment status in said patient.

This invention provides an amadoriase having improved specific activity on a glycated substrate, compared with conventional amadoriase. Provided is an amadoriase comprising a substitution of the amino acid at the position corresponding to position 64 of the amino acid sequence as shown in SEQ ID NO: 1 with an amino acid selected from the group consisting of glycine, serine, methionine, leucine, threonine, valine, and isoleucine, a method for measurement of HbA1c, and a reagent kit for measurement of HbA1c using such amadoriase. Such method and kit for measurement enable rapid, simple, and accurate quantification of HbA1c.

The present invention is directed to a bio-fluid detector such as a hemoglobin detector having the capability of receiving, storing and transmitting health information utilizing a portable transmitter and receiver including electronic PDAs such as cell phones. Further, the present invention utilizes a non-invasive hemoglobin detector that is connected to a portable transmitter-receiver such as PDAs including, but not limited to, cell phones.

The present invention relates to simple, low-cost, rapid paper-based diagnostic devices and their methods of use.